Volume 13, Number 1—January 2007
Research
Model for Assessing Human Papillomavirus Vaccination Strategies
Elamin H. Elbasha*
, Erik J. Dasbach*, and Ralph P. Insinga*
, Erik J. Dasbach*, and Ralph P. Insinga*Table 3
Incremental cost-effectiveness ratios of alternative HPV vaccination strategies with varying start age of vaccination*
| Strategy | Discounted total | Incremental | |
|---|---|---|---|
| Costs | QALY | $/QALY† | |
| 18-y-old women plus 18- to 24-y-old female catch-up | 73,553,847 | 2,699,192 | 1,858 |
| 15-y-old female adolescents plus 15- to 24-y-old female catch-up | 73,895,046 | 2,699,214 | Weakly dominated |
| 12-y-old girls plus 12- to 24-y-old female catch-up | 74,815,667 | 2,699,343 | 8,357 |
| 18-y-old women and men plus 18- to 24-y-old female and male catch-up | 77,535,383 | 2,699,385 | Weakly dominated |
| 15-y-old female and male adolescents plus 15- to 24-y-old female and male catch-up | 78,455,750 | 2,699,404 | Weakly dominated |
| 12-y-old female and male adolescents plus 12- to 24-y-old female and male catch-up program | 81,761,210 | 2,699,506 | 42,697 |
*Assumes cost of vaccination series is US $360, duration of protection is lifelong, and coverage rate of 50% among age 15- to 24-y-olds. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A. A strategy is weakly dominated if there is another more effective program that has a incremental cost-effectiveness ratio.
